Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron and Sanofi-Aventis collaborate to develop antibodies
As part of the research agreement, Sanofi-Aventis will make an $85 million upfront payment to Regeneron and will fund up to $475 million of research over the next
As part of the research agreement, Sanofi-Aventis will make an $85 million upfront payment to Regeneron and will fund up to $475 million of research over the next
Mr Smither spent more than nine years at Amgen, where he advanced rapidly through financial management positions for business units and subsidiaries based in Europe and the US.
In placebo-controlled clinical trials of over 800 people with diabetic neuropathic pain, significant and sustained reductions in pain scores were seen versus placebo. A similar filing made to
Under the terms of the agreement, Galapagos stands to receive up to $2.4 million in upfront and research fees over the next two years, and up to $5.7
Under the agreement, which is effective February 1, 2008, Cardinal Health will supply these customers with Presource kits and procedure-based delivery system (PBDS) modules for all areas within
The antibody is a previously unidentified marker for the analysis of pluripotent stem cells in immunocytochemistry and other immunological techniques. This antibody was developed by Abeome in conjunction
Under the terms of the agreement, the companies will share responsibilities for development and commercialization of the anti-L1 monoclonal antibody (L1 MAb). Celltrion will conduct process development and
In 2005, Artemis and Taconic established a strategic alliance which combined Artemis’s technology platform in mouse genetics and genomics with Taconic’s expertise in breeding mice and rats, quality
The company said that WinRho SDF (Rho(D) Immune Globulin (Human)) liquid provides a convenient alternative to the lyophilized (freeze-dried) version of the therapeutic by eliminating the need for
ImmuFact IMP321 is a potent natural human immunostimulatory factor designed to amplify the T-cell immune response. It can be used either as an immunopotentiator in therapeutic vaccines or